Immunome Inc
IMNM
NASDAQ
Biotechnology
$27.20
USD
+0.78 (+2.95%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $3.00B
Volume 759.6K
Revenue
$0
TTM
-100.0%
YoY
Gross Margin
—
TTM
— YoY
Net Income
$-254.32M
TTM
-19.7%
YoY
Operating Cash Flow
$-208.79M
TTM
-16.9%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 4.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | +69.8% | -100.0% | -100.0% | -100.0% | -100.0% |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 4.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 10.0 | 10.9 | 12.1 | 13.0 | 18.3 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 50.5 | 60.1 | 72.9 | 59.3 | 78.1 |
Operating Income | -46.5 | -60.1 | -72.9 | -59.3 | -78.1 |
EBITDA | -45.8 | -59.5 | -72.2 | -58.7 | -77.2 |
Other Income / Expense | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Other Income / Expense | 3.1 | 2.7 | 3.0 | 5.5 | 5.0 |
Income Before Income Taxes | -43.4 | -57.5 | -69.9 | -53.8 | -73.1 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -43.4 | -57.5 | -69.9 | -53.8 | -73.1 |
Consolidated Net Income / Loss | -43.4 | -57.5 | -69.9 | -53.8 | -73.1 |
Net Income Attributable to Common Shareholders | -43.4 | -57.5 | -69.9 | -53.8 | -73.1 |
Basic EPS | -$0.50 | -$0.65 | -$0.74 | -$0.48 | -$0.65 |
Diluted EPS | -$0.50 | -$0.65 | -$0.74 | -$0.48 | -$0.65 |
Basic Shares Outstanding | 87.0M | 88.0M | 95.0M | 113.1M | 113.3M |
Diluted Shares Outstanding | 87.0M | 88.0M | 95.0M | 113.1M | 113.3M |